Pharmafile Logo

The science is shifting in oncology: Are you ready to evolve with it?

August 19, 2025 | Inizio, oncology 

- PMLiVE

Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke.

This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic breast cancer introduced a ground-breaking endpoint – patients progression-free at four years – challenging long-held assumptions.

Key themes included the rise of CAR-T therapies in solid tumors, the dominance of ADCs, and the expanding role of biomarkers in driving precision medicine. Emerging tools like AI-powered biomarker detection and ctDNA for real-time monitoring are reshaping how sequencing, resistance, and adaptive treatments are approached.

Beyond the science, ASCO® 2025 underscored a new strategic imperative: it’s no longer enough to track progress – we must rethink how we plan, communicate, and act on these advances.

Read Patty’s full article here. Watch Inizio’s webinar recap Beyond the booth: Big ideas, smart spaces & strategic insights from ASCO® 2025 on demand for the full breakdown.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Article

How will COVID-19 affect uptake of vaccinations against other diseases?

Podcast

Living With Chronic Illness (Series one)

Webcast

China: How pharma can maximize success in this rapidly changing emerging market

Article

Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma

Infographic

Migraine market snapshot

Webcast

Monitoring the impact of COVID-19 on the market access landscape

Live webinar from Singapore

Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19

Guide

UX research

Article: Why pharma must trust the science of behaviour

In a recent interview with PME Magazine, Dan Coffin, Director explains why the application of behavioural science will be key to better health far beyond COVID-19.Read the full article here:...

Case study

Using qualitative conjoint to assess willingness-to-pay